At diagnosis, our patient had a deletion of 11q23 involving monosomic KMT2A loss without rearrangement, which is considered an intermediate-risk feature, and U2AF1 mutation, which is considered an adverse-risk myelodysplasia-related gene mutation [2]. This evidence concerns the gene KMT2A and Myelodysplasia.